Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Canada
  4. CANADIAN NATIONAL STOCK EXCHANGE
  5. PharmaTher Holdings Ltd.
  6. News
  7. Summary
    PHRM   CA71716H1082

PHARMATHER HOLDINGS LTD.

(PHRM)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

PharmaTher : Begins Phase 2 Clinical Trial of Ketamine for the Treatment of Parkinson's Disease

10/06/2021 | 10:29am EST


© MT Newswires 2021
All news about PHARMATHER HOLDINGS LTD.
11/30PharmaTher Granted New Japanese Patent for KETABET™ (Ketamine Combination Formula..
AQ
11/24PharmaTher Holdings Ltd. Applies for FDA Orphan Drug Designation for Ketamine to Treat ..
CI
11/24PharmaTher Applies for FDA Orphan Drug Designation for Ketamine to Treat Rare Neurologi..
AQ
11/11PharmaTher Announces Positive Research Results for Psilocybin Microneedle Patch
AQ
11/11PharmaTher Announces Positive Research Results for Psilocybin Microneedle Patch
CI
11/03PharmaTher in Research Collaboration Agreement with Revive Therapeutics for Development..
MT
11/03PharmaTher Enters into Research Collaboration Agreement with Revive Therapeutics for De..
GL
11/03Revive Therapeutics Enters into Research Collaboration Agreement with PharmaTher for De..
AQ
11/01PharmaTher Provides Research Update on Microneedle Patch Delivery Technologies for Psyc..
GL
11/01PharmaTher Holdings Ltd. Provides Research Update on Microneedle Patch Delivery Technol..
CI
More news
Financials
Sales 2022 - - -
Net income 2022 - - -
Net Debt 2022 - - -
P/E ratio 2022 -
Yield 2022 -
Capitalization 28,1 M 22,0 M 21,9 M
Capi. / Sales 2022 -
Capi. / Sales 2023 -
Nbr of Employees -
Free-Float 77,5%
Chart PHARMATHER HOLDINGS LTD.
Duration : Period :
PharmaTher Holdings Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 1
Last Close Price 0,33 CAD
Average target price 5,00 CAD
Spread / Average Target 1 438%
Managers and Directors
Fabio Chianelli Chairman & Chief Executive Officer
Carmelo K. Marrelli Chief Financial Officer
Owen van Cauwenberghe Head-Research & Development
Beverly James Incledon Director
Christian Scovenna Director
Sector and Competitors
1st jan.Capi. (M$)
PHARMATHER HOLDINGS LTD.1.56%22
JOHNSON & JOHNSON1.27%419 583
ROCHE HOLDING AG17.62%341 364
PFIZER, INC.44.09%304 610
NOVO NORDISK A/S64.51%244 010
ELI LILLY AND COMPANY47.55%222 641